Recursion Pharmaceuticals Insider Blake Borgeson Sells $155K of Stock
Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals, Inc. at $3.88 a share, worth $155K in total on Nov 3, 2026. Shares held after the trade: 6,068,287 (-0.7%).
Recursion Pharmaceuticals reported a net loss of $119.0 million for the third quarter of 2026, an improvement from the $162.3 million loss in the prior year period. Total revenue increased significantly to $18.6 million for the quarter, while the company maintained a strong liquidity position with $549.9 million in cash and cash equivalents as of September 30, 2026.
Recursion Pharmaceuticals reported Q3 2026 financial results, highlighting clinical data for REC-4881 and REC-1245 and the appointment of Fred Hassan as Chair of the Board. The company extended its cash runway into 2029 following an October follow-on offering and noted that Sanofi has optioned the first development candidate from their collaboration.
Term
Q3 2026
“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”
Najat Khan, Ph.D., President and Chief Executive Officer of Recursion
Recursion Pharmaceuticals entered into an underwriting agreement to raise approximately $200 million through a public offering of 61,540,000 shares of Class A common stock at $3.25 per share. The company also announced that Sanofi exercised an option for a first-in-class immunology development candidate under their existing collaboration, triggering a $10 million milestone payment. Proceeds from the equity raise are expected to extend the company's cash runway into 2029.
Recursion Pharmaceuticals Insider Blake Borgeson Sells $242K of Stock
Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals, Inc. at $4.84 a share, worth $242K in total on Oct 6, 2026. Shares held after the trade: 6,108,287 (-0.8%).
Recursion Pharmaceuticals Insider Robert Hershberg Sells $125K of Stock
Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals, Inc. at $5.00 a share, worth $125K in total on Oct 6, 2026. Shares held after the trade: 162,156 (-13.4%).
Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M
Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.